Lori Anne Kunkel
CIK 1536368 · Acting-Chief Medical Officer · last filed 2026-07-08
Lori Anne Kunkel is an Acting-Chief Medical Officer who has filed 50 SEC Form 4 insider transactions across 7 companies since 2015. The most recent filing shows the insider sold $504.9K of ELVN on Jul 8, 2026. Across all open-market trades the lifetime net is −$10.6M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $4.3M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$4.32M
7
50
-$10.61M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ELVN | Director | 47,773 | $53.76 | $2.57M | -$504.9K | 1 | 2026-07-08 |
| IMRA | Director | 51,884 | $14.49 | $751.8K | -$345.4K | 5 | 2026-06-09 |
| ORIC | Director | 84,200 | $11.91 | $1.00M | $0 | 11 | 2026-01-06 |
| NRIX | Director | 0 | $24.15 | $0 | $0 | 6 | 2025-05-19 |
| CRIS | Director | 56 | $4.83 | $270 | -$15.6K | 8 | 2022-01-31 |
| Forte Biosciences, Inc. (TOCA) Delisted | Acting-Chief Medical Officer | — | — | — | $0 | 4 | 2019-10-04 |
| Loxo Oncology, Inc. (LOXO) Delisted | Director | 500 | — | — | -$9.75M | 10 | 2019-02-15 |
Recent Filings
50 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-08 | ELVN | Sell (S) | −10,000 | -$504.9K | EDGAR |
| 2026-06-09 | IMRA | Sell (S) | −10,000 | -$345.4K | EDGAR |
| 2026-06-05 | ELVN | Notice (144) | −20,000 | -$709.8K | EDGAR |
| 2026-02-17 | IMRA | Grant (A) | — | $0 | EDGAR |
| 2026-01-06 | ORIC | Grant (A) | — | $0 | EDGAR |
| 2025-12-19 | IMRA | Exer (M) | +15,958 | $17.9K | EDGAR |
| 2025-12-09 | ORIC | Exer (M) | +10,000 | $79.0K | EDGAR |
| 2025-12-05 | ORIC | Exer (M) | +5,534 | $20.8K | EDGAR |
| 2025-05-19 | NRIX | Grant (A) | — | $0 | EDGAR |
| 2025-03-04 | ORIC | Exer (M) | +48,166 | $233.5K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.